PMID- 28387160
OWN - NLM
STAT- MEDLINE
DCOM- 20170724
LR  - 20181202
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 18
IP  - 7
DP  - 2017 May
TI  - Long-term treatment in pediatric asthma: an update on chemical pharmacotherapy.
PG  - 667-676
LID - 10.1080/14656566.2017.1317747 [doi]
AB  - Asthma is the most common chronic disease in childhood, affecting approximately 
      10% of all children, and is the leading cause of hospitalization in developed 
      countries. In this paper we aimed to review the evidence on chemical 
      pharmacotherapy for long-term treatment of pediatric asthma, according to the 
      latest updates. Area covered: Long-term treatment, essential for controlling 
      symptoms and reducing future risks including exacerbations and decline in lung 
      function, includes control agents such as inhaled corticosteroids, long-acting 
      beta2-adrenergic agonists, and leukotriene modifiers. More recent strategies 
      based on the use of a biological drug such as omalizumab, which is a monoclonal 
      antibody directed against immunoglobulin E (IgE), can be considered in selected 
      patients with severe asthma. Expert opinion: In the near future, the challenge of 
      childhood asthma treatment will be to improve the chemical drugs that already 
      exist as well as to carefully characterize the several different asthma subtypes, 
      with special regard to children with severe disease. A better definition of 
      patient features, made possible by the current advanced knowledge of the 
      pathobiology of severe asthma, can ultimately allow the identification of 
      specific phenotypes and endotypes of severe asthma, aimed to personalize 
      pharmacological treatment.
FAU - Vitale, Carolina
AU  - Vitale C
AD  - a Department of Medicine, Surgery and Dentistry, Section of Respiratory Diseases 
      , University of Salerno , Salerno , Italy.
FAU - Maglio, Angelantonio
AU  - Maglio A
AD  - a Department of Medicine, Surgery and Dentistry, Section of Respiratory Diseases 
      , University of Salerno , Salerno , Italy.
FAU - Pelaia, Corrado
AU  - Pelaia C
AD  - b Department of Medical and Surgical Sciences, Section of Respiratory Diseases , 
      University "Magna Graecia" of Catanzaro , Catanzaro , Italy.
FAU - Vatrella, Alessandro
AU  - Vatrella A
AD  - a Department of Medicine, Surgery and Dentistry, Section of Respiratory Diseases 
      , University of Salerno , Salerno , Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170420
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Adrenergic beta-2 Receptor Agonists)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antibodies, Monoclonal)
RN  - 2P471X1Z11 (Omalizumab)
SB  - IM
MH  - Adrenal Cortex Hormones/*therapeutic use
MH  - Adrenergic beta-2 Receptor Agonists/therapeutic use
MH  - Anti-Asthmatic Agents/*therapeutic use
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Asthma/*drug therapy
MH  - Child
MH  - Chronic Disease
MH  - Hospitalization
MH  - Humans
MH  - Omalizumab/therapeutic use
OTO - NOTNLM
OT  - Childhood asthma
OT  - long term treatment of asthma
OT  - pharmacotherapy
EDAT- 2017/04/08 06:00
MHDA- 2017/07/25 06:00
CRDT- 2017/04/08 06:00
PHST- 2017/04/08 06:00 [pubmed]
PHST- 2017/07/25 06:00 [medline]
PHST- 2017/04/08 06:00 [entrez]
AID - 10.1080/14656566.2017.1317747 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2017 May;18(7):667-676. doi: 
      10.1080/14656566.2017.1317747. Epub 2017 Apr 20.